Closed

Medical Technology and Devices: from Lab to Patient

HORIZON EIC Grants

Basic Information

Identifier
HORIZON-EIC-2021-TRANSITIONCHALLENGES-01-01
Programme
EIC Transition Challenges 2021
Programme Period
2021 - 2027
Status
Closed (31094503)
Opening Date
May 19, 2021
Deadline
September 22, 2021
Deadline Model
single-stage
Budget
€40,500,000
Keywords
Behavioural neuroscience (e.g. sleep, consciousnesTechnology implementationMedical devicesFunctional biologyBiomedical softwareCell biology, MicrobiologyComputational biologyClinical managementHardware technology (RFID, chips, sensors, etc.)Mass SpectrometrySensor Technology and ComponentsNeuroimaging and computational neuroscienceBioremediation, diagnostic biotechnologies (DNA chCardiovascular systemSignal processingApplied genetic engineering, transgenic organisms,Gene therapy, cell therapy, regenerative medicineTomographyOpto-electronics: Laser, optics and related deviceGender in biochemistry and molecular biologyLicensingBiomechanicsChromatographySurgical roboticsTechnology evaluationCompetitiveness, innovation, research and developmRisk analysisAuditive systemCopyrightsMedical engineering and technologyDiagnostic tools (e.g. genetic, imaging)Locomotion systemSensory systems (e.g. visual system, auditory systBusiness developmentMetabolismElectronic patient filesChemical sciencesScientific computing, simulation and modelling tooStart-up companiesTranscriptomicsMedical biotechnologyCardiovascular diseasesEndocrinology and metabolism (including diabetes,Regenerative medicineRespiratory systemsBrain simulation; brain modelling; molecular neuroFeasibility analysisRadiology, nuclear medicine and medical imagingPhysiological biophysicsInteraction, Multimodal, Brain-Computer-InterfacesFinancePatentsPersonalised medicineNanotechnology, nano-materials, nano engineeringMolecular electronicsRegulatory framework for innovationArtificial intelligenceNano-processes (applications on nano-scale)Biophotonics, Imaging, image and data processingTechnology commercialisationCognition (e.g. learning, memory, emotions, speechMorphology and functional imaging of cellsPharmacology, pharmacogenomics, drug discovery andMedical sciencesElectrochemistry, electrodialysis, microfluidics,Physiology Science & Medical technologiesRegulatory and StandardizationBiomaterial engineeringBioprocessing technologies (industrial processes rInfectious diseasesOptical sensorsOncologySevere acute respiratory syndromeMaterials engineering (biomaterials, metals, ceramBiomedical engineeringBiomodellingTissue engineeringTheoretical and computational chemistryMolecular biophysicsMicroscopy and spectroscopyMedical laboratory technology (including laboratorDesign innovationElectrical and electronic engineering: semiconductImaging, image and data processingNeurobiologyProteomicsNeurodegenerative disordersPrototypingIndustrial IoT and Control SystemsSimulation engineering and modellingHealth care sciences and services (including hospiTechnology transferDiagnostic and implantable devices, environmentalAtomic, molecular and chemical physics (physics ofArtificial organsSpectroscopyInvestment readinessTechnological innovationHealthcare systemGraphene, layered materialMachine learning, statistical data processing andEconomics of innovationStem cell therapyCertification, Verification, Validation, TechnicalIPR managementNetworks (communication networks, sensor networks,SurgeryGene therapyComputer hardware and architectureRadiotherapyPerinatal healthInternet of Things, embedded/pervasive systemsPhysiological modellingTechnologies involving identifying the functioningIncremental innovationMetabolomicsDisruptive innovationBiological systems analysis, modelling and simulatQuantum optics and quantum informationCloud, Edge and VirtualisationBusiness model innovationNanophysics: nanoelectronics, nanophotonics, nanomMarket analysisMicrobiologyBiochemistry and molecular biologyNeuroinformaticsNano-materials (production and properties)TrademarksDigital AgendaSustainable innovationCardiac ImagingCost estimation / analysisQuantum Technologies (computing/communication)Screening programmeData marketsEntrepreneurshipNeurological disorders (e.g. Alzheimer's disease,Blockchain and Distributed Ledger Technology (DLT)Brain researchBiomaterials (as related to medical implants, deviRobotics for healthcarePhotonicsPatient safetyLaser-based manufacturing and materials processingOptical engineering, photonics, lasersIntensive careBioinformatics, biocomputing, and DNA and moleculaInnovation managementMarket researchCritical care medicine and Emergency medicineClinical bioinformaticsHigh-performance computing (HPC)Biological sciencesExploitation of resultsCompetitor analysisMaterials for sensorsMental disordersBioelectricityBusiness planHuman Machine Interface (HMI)Technologies involving the manipulation of cells,Computer sciences - Operating systems (software)BiomarkersMicro- and nanoelectronics, optoelectronicsBiophotonics and medical applicationsNon-invasiveMarket studiesBusiness analysisCardiac and Cardiovascular systemsClinical trialsOrganic chemistryDiagnosticsPhotonic/Optical Materials and Device Technology

Description

Scope:

EU-funded early-stage Research on novel Medical Technologies and Devices is uncovering unique opportunities to benefits patients and support clinicians.

Medical Technology and Devices businesses are facing long and capital-intensive product development cycles, complex regulatory procedures, slow market uptake requiring the support of key opinion leaders and intensive follow-up with early adopters. In addition to a mature technology, a well thought-out and realistic exploitation path with emphasis on achieving market traction as proof of both clinical and market potential of the idea is needed.

Proposal submitted to this transition challenge call should aim to:

  • Perform the necessary R&D to advance from an existing proof-of-principle technology to a mature version to initiate clinical evaluation.
  • Develop an exploitation strategy, qualitatively and quantitatively outlining the proposed path to patient and describing an investable proposition.

Proposal submitted to this call can target any technology addressing important health needs in the direct clinical treatment and care of patients.

The EIC considers proposals with a requested EU contribution of up to a EUR 2.5 million and a duration of up to 3 years as appropriate.

For further information on your eligibility, please refer to the EIC Work Programme 2021 in section III.2.1.

View on EU Portal →

Eligibility & Conditions

1. Admissibility conditions:

Your proposal must build on results (demonstrated proof of principle) achieved within an eligible project. As Transition funding is a new scheme, for 2021 it is restricted to applications based on results generated by the following eligible projects:

  • EIC Pathfinder projects (including projects funded under EIC pilot Pathfinder, Horizon 2020 FET-Open, FET-Proactive) and FET Flagships calls (including ERANET calls under the FET work programme)
  • European Research Council (ERC) Proof of Concept projects

If you are applying on the basis of an eligible project for which the grant is still active, you may apply if the project has been active for at least 12 months (i.e. the start date of the grant is more than 12 months before the date of the Transition call deadline).

If you are applying on the basis of an eligible project which has already been completed, you may apply within 24 months of the completion of the project (i.e. the end date of the grant for the eligible project is less than 24 months from the date of the Transition call deadline).

You do not need to be a participant, Principle Investigator or result owner of the previous projects; on the contrary, new participants are welcome and encouraged to apply. However, you must demonstrate that you are the Intellectual Property Rights (IPR) owner or holder, or have the necessary rights to commercialise the IPR of the linked Pathfinder, FET or ERC Proof of Concept project results to be further developed. You therefore must specify in your application the result and relevant IP to be developed, and include written evidence from the relevant owner(s) of the result(s), which confirms the existence of the necessary agreements with you, including on IPR.

You can apply for EIC Transition either as:

  • A single legal entity established in a Member State or an Associated Country (‘mono-beneficiary’) if you are an SME or a research performing organisation (university, research or technology organisation, including teams, individual Principle Investigators and inventors in such institutions who intend to form a spinout company). Larger companies (i.e. which do not qualify as SMEs) are not eligible to apply as a single legal entity; or
  • A small consortium of minimum two and maximum five independent legal entities (‘multi-beneficiary’) that may for example include universities, research organisations, SMEs or larger companies, user/customer organisations or potential end users (e.g. hospitals, utilities, industry, regulatory and standardisation bodies, public authorities).

Your proposal will only be evaluated if it is admissible and eligible (see Annex 2 as well as Annex 3 of the EIC Work Programme 2021 for eligibility of third country applicants).

Proposal page limits and layout: Sections 1 to 3 of your proposal must consist of a maximum of 25 A4 pages.

 

2. Eligible countries: described in section II.3 and in Annex 3 of the EIC Work Programme 2021.

 

3. Financial and operational capacity and exclusion: described in Annex 2 of the EIC Work Programme 2021.

 

4. Evaluation and award:

 

5. Legal and financial set-up of the grants: please refer to the Model Grant Agreement (MGA) used for EIC actions under Horizon Europe

 

Call document and annexes:
EIC Work Programme 2021
Standard Application Form (EIC Transition Open 2021)
Frequently Asked Questions (FAQ)
MGA used for EIC actions under Horizon Europe (HE General MGA)

 

Additional documents:
EU Financial Regulation 2018/1046
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms & Conditions
Funding & Tenders Portal Privacy Statement

Support & Resources

 

Online Manual is your guide on the procedures from proposal submission to managing your grant.

Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.

Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.

Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.

IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

European IPR Helpdesk assists you on intellectual property issues.

CEN and CENELEC, the European Standards Organisations advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at [email protected].

The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.

 

Partner Search Services help you find a partner organisation for your proposal.

 

Latest Updates

No updates available.